	Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis. Urol Oncol Subiela JD, González-Padilla DA, Scilipoti P, Slusarczyk A, Pichler R, Guerrero-Ramos F, Artiles-Medina A, Caño-Velasco J, Aumatell J, Krajewski W, Mertens LS, Teoh JY, Contieri R, Maiorano BA, Claps F, Del Giudice F, D'Andrea D, Gajate P, Guerrero P, Gallioli A, Villacampa F, Acosta EA, Lozano F, Carrion A, Afferi L, Crespo L, Marcq G, Soria F, Moschini M, Grobet-Jeandin E, Albisinni S, Alvarez-Maestro M, San-José Manso L, Gomez Dos Santos V, Roupret M, Burgos Revilla FJ, Pradere B, Buisan O, Young Academic Urologist (YAU) Urothelial Carcinoma Working Group. PMID: 42881094 [PubMed - as supplied by publisher]
	Feasibility of Laparoscopic Partial Cystectomy for Bladder Paraganglioma: A Four-Case Series. Asian J Endosc Surg Sato T, Hayata N, Miura T, Mishina M, Kitamura T, Tsuiki M, Hijikata Y, Kuwahara R, Kasahara S, Moriyoshi K, Kanno T. PMID: 42880937 [PubMed - indexed for MEDLINE]
	Intrapancreatic Fat Deposition and Prostate Cancer Risk: A Primary Case-Control Study. Technol Cancer Res Treat Wang H, Li H, Zhang K, Wu L, Wang C, Fang D, Yu Y, Yang X, Sun S, Chen X, Bi S, Wen H. PMID: 42880771 [PubMed - indexed for MEDLINE]
	Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study. Urology Ergas IJ, Zimbalist A, Haque R, Lee VS, Roh JM, Cannavale KL, Wang Z, Loo RK, Aaronson DS, Quesenberry CP Jr, Kushi LH, Tang L, Kwan ML. PMID: 42880421 [PubMed - as supplied by publisher]
	Diagnostic performance of post-chemoradiotherapy nacVI-RADS for identifying pathological complete response in muscle-invasive bladder cancer. Eur J Radiol Fukui K, Kobayashi M, Yoshida S, Arita Y, Yamagiwa K, Tsuchiya J, Fujiwara M, Aslan S, Tasdemir MN, Fujii Y, Tateishi U. PMID: 42880152 [PubMed - as supplied by publisher]
	Urinary cell TWIST1 methylation as a non-invasive dual biomarker: A Multicenter study for early detection and recurrence monitoring in bladder cancer. Cancer Genet Li Y, Li X, Jiang L, Sun L, Wang F, Liu H, Xu Y, Zhou Y, Li Q, Fu S, Wang X, Du H, Li X, Yan Z, Li M, Mo Q, Li X, Li C, Yang X, Chen H, Xu Y, Shao J, Meng H, Liu Z. PMID: 42879988 [PubMed - as supplied by publisher]
	Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapy. Pathobiology Shi Y, Zong X, Lian J, Wang Y. PMID: 42879368 [PubMed - as supplied by publisher]
	Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment deâ€‘intensification strategies. Expert Rev Anticancer Ther Catalano M, Roviello G. PMID: 42879203 [PubMed - as supplied by publisher]
	Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol Hannan R, Lin L, Assadi R, Pop LM, Robles L, Zhang F, Mulvaney O, Gao A, Kapur P, Pedrosa I, Garant A, Yang D, Ahn C, Wait M, Timmerman R, Margulis V. PMID: 42879162 [PubMed - as supplied by publisher]
	Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer. JAMA Netw Open Nandakumar V, Jo Y, Ostrowski M, Gebrael G, Ozay ZI, Lin E, Goel K, Revillo R, Upadhyay L, Agarwal T, Sayegh N, Mathew Thomas V, Li H, Agarwal N, Swami U. PMID: 42879153 [PubMed - indexed for MEDLINE]
	Association of immune checkpoint-related polymorphisms in PD-1, PD-L1, and CTLA-4 genes with susceptibility to genitourinary cancer: a meta-analysis. Immunol Res Chen CH, Hu SW, Wu CC, Wang YH. PMID: 42878951 [PubMed - indexed for MEDLINE]
	Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group. Eur Radiol Brembilla G, Messina E, Barret T, Caglic I, Cuocolo R, de Rooij M, Figueiras RG, Girometti R, Guerra A, Hamm CA, Manenti G, Ponsiglione A, Penna RR, Richenberg J, Sala E, Thoeny H, Turgut AT, Vilanova JC, Withey SJ, Zawaideh J, Barentsz J, Panebianco V, ESUR Prostate MRI Working Group. PMID: 42878808 [PubMed - as supplied by publisher]
	Association between Trust and Patient-Reported Outcomes and Experience in Prostate Cancer Patients. Med Decis Making Chhatre S, Gallo JJ, Guzzo T, Morales KH, Vapiwala N, Malkowicz SB, Jayadevappa R. PMID: 42878269 [PubMed - as supplied by publisher]
	Bisphenol A and prostate cancer: from population exposure to context-dependent mechanisms and translational implications. Front Cell Dev Biol Li Z, Cao H, Ye Z, Wang B, Li S, Wu H, Bai Z, Gao B. PMID: 42877333 [PubMed]
	Dual-targeting theranostic strategies to overcome receptor heterogeneity in neuroendocrine prostate cancer. RSC Med Chem Dewangan S, Kumar BV, Meher N. PMID: 42877116 [PubMed - as supplied by publisher]
	Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis. Front Oncol Fan L, Wu S, Xie X, Zheng Y, Chen L, Ding R. PMID: 42877008 [PubMed]
	First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Immunol Jia Y, Zhao S, Wang X, Kang S. PMID: 42876805 [PubMed - indexed for MEDLINE]
	Lower proportion of bladder cancer diagnosed at unscheduled hospitalization after introduction of standardized care pathways in Sweden. Scand J Urol Liedberg F, Bobjer J, Hagberg O, Aljabery F, Gårdmark T, Jahnson S, Jerlström T, Kjölhede H, Ströck V, Söderkvist K, Ullén A, Holmberg L, Häggström C. PMID: 42876402 [PubMed - indexed for MEDLINE]
	Real-World Comparative Effectiveness of Lobaplatin Versus Epirubicin and Gemcitabine for Post-TURBT Intravesical Therapy in Non-Muscle-Invasive Bladder Cancer. Arch Esp Urol Han S, Li X, Ma L, Hu Z, Jia Z, Wu M, Xing N. PMID: 42876134 [PubMed - indexed for MEDLINE]
	Metabolic Syndrome and Bladder Cancer Risk: A Meta-Analysis of Cohort Studies. Arch Esp Urol Teng H, Chen J, Qian J, Chen L, Zhu Y, Tang T, Wang P, Xu X. PMID: 42876132 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 182201

Page 1 of 9111



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy